Original antigenic sin and immune system flexibility

The short version: your first infection or vaccine can lock in your antibody response, making it harder to adapt to new viral strains.

Original antigenic sin is the immune system’s tendency to favor memory of the first version of a virus it ever saw, even when a new version shows up. This can reduce immune flexibility. The evidence shows this is real, measurable, and can work against you.

In children, vaccine imprinting directly shapes which variants they are vulnerable to. A 2026 study found that children primed with the ancestral (Wuhan-Hu-1) vaccine had equal neutralizing antibody rates against both the newer BA.3.2 and XFG variants. But children primed with an Omicron-based vaccine were ten times more likely to have protective antibodies against XFG than against BA.3.2 [5]. That is a concrete, measurable tradeoff created by the choice of vaccine.

For influenza, repeated annual vaccination blunts the immune response. A 2020 pilot study of 20 adults showed that people who had 3-5 flu shots in the prior 5 years had significantly lower antibody-secreting cell responses and lower antibody fold increases after vaccination compared to people with 0-2 prior shots [1]. A 2025 study of healthcare workers found the same pattern: those vaccinated every year had lower post-vaccination antibody titers than those with fewer prior vaccinations [7]. The pattern holds across both COVID-19 and flu.

Animal experiments confirm the mechanism can be overcome. A 2012 mouse study found that adding an adjuvant (pertussis toxin or nanoemulsion) to the second vaccine dose, or giving a booster of the second strain, broke through original antigenic sin and produced protective antibodies against the new strain [15]. This suggests the problem is not inevitable, but the standard formulation does not solve it.

My call: repeated boosting with updated vaccines does not fully overcome immune imprinting and can leave you with a narrower antibody repertoire against new variants. The evidence for this is moderate in quality: well-documented in multiple studies, mostly using antibody surrogates rather than hard infection outcomes, and the long-term clinical significance of narrower antibody breadth is not directly tested. Confidence: moderate.